sample,study,diagnosis,group,age,sex,bmi,country,region,pcr_primers,platform,disease_name,title,disease_name_ab,host_body_mass_index
SRR8351974,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351975,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351976,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351977,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351978,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351979,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351980,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351981,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351982,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351983,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351984,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351985,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351986,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351987,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351988,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351989,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351990,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351991,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351992,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351993,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351994,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351995,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351996,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351997,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8351998,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352000,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352001,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352002,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352003,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352004,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352005,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352006,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352007,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352008,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352009,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352010,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352011,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352012,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352013,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352014,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352015,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352016,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352017,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352018,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352019,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352020,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352021,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352022,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352023,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352024,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352025,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352026,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352027,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352028,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352029,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352030,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352031,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352032,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352033,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352034,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352035,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352036,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352037,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352038,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352039,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352040,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352041,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352042,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352043,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352044,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352045,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352046,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352047,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352048,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352049,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352050,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352051,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352052,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352053,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352054,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352055,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352056,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352057,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352058,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352059,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352060,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352061,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352062,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352063,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352064,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352065,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352066,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352067,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352068,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352069,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352070,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352071,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352072,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352073,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352074,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352075,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352076,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352077,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352078,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352079,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352080,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352081,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352082,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352083,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352084,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352085,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352086,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352087,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352088,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352089,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352090,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352091,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352092,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352093,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352094,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352095,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352096,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352097,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352098,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352099,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352100,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352101,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352102,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352103,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352104,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352105,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352106,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352107,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352108,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352109,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352110,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352111,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352112,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352113,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352114,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352115,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352116,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352117,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352118,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352119,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352120,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352121,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352122,PRJNA510730,GC,0,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352123,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352124,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR8352125,PRJNA510730,GP,1,,,,Italy,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321049,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321050,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321051,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321052,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321053,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321054,PRJNA510730,GC,0,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321055,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321056,PRJNA510730,GC,0,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321057,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321058,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321059,PRJNA510730,GC,0,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321060,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321061,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321062,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321063,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321064,PRJNA510730,GC,0,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321065,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321066,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321067,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321068,PRJNA510730,GC,0,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321069,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321070,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321071,PRJNA510730,GC,0,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321072,PRJNA510730,GC,0,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321073,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321074,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321075,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321076,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321077,PRJNA510730,GC,0,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321078,PRJNA510730,GC,0,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321079,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321080,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321081,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321082,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321083,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321084,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321085,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321086,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321087,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321088,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321089,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321090,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321091,PRJNA510730,GC,0,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321092,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321093,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321094,PRJNA510730,GC,0,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321095,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321096,PRJNA510730,GC,0,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321097,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
SRR11321098,PRJNA510730,GP,1,,,,Italy: Rome,V3-V4,,Illumina MiSeq,PD,Dysbiosis of gut microbiota in a selected population of Parkinson's patients,PD,
ERR1513669,PRJEB14674,Control,0,,female,28.34,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513670,PRJEB14674,Control,0,,female,33.12,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513671,PRJEB14674,Control,0,,female,32.28,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513672,PRJEB14674,Control,0,,female,24.44,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513673,PRJEB14674,Control,0,,male,25.06,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513674,PRJEB14674,Control,0,,male,24.47,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513675,PRJEB14674,Control,0,,male,24.82,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513676,PRJEB14674,Control,0,,female,31.17,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513677,PRJEB14674,Control,0,,male,33.96,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513678,PRJEB14674,Control,0,,female,25.44,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513679,PRJEB14674,Control,0,,male,26.04,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513680,PRJEB14674,Control,0,,male,26.04,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513681,PRJEB14674,Control,0,,male,25.4,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513682,PRJEB14674,Case,1,,female,21.92,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513683,PRJEB14674,Case,1,,male,32.07,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513684,PRJEB14674,Case,1,,male,25.33,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513685,PRJEB14674,Case,1,,male,34.66,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513686,PRJEB14674,Case,1,,male,27.44,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513687,PRJEB14674,Case,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513688,PRJEB14674,Case,1,,female,19.53,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513689,PRJEB14674,Case,1,,male,22.87,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513690,PRJEB14674,Case,1,,male,20.03,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513691,PRJEB14674,Case,1,,female,36.84,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513692,PRJEB14674,Case,1,,male,20.28,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513693,PRJEB14674,Case,1,,female,25.05,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513694,PRJEB14674,Case,1,,male,32.48,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513695,PRJEB14674,Case,1,,male,29.02,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513696,PRJEB14674,Case,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513698,PRJEB14674,Case,1,,female,20.5,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513699,PRJEB14674,Case,1,,male,31.47,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513700,PRJEB14674,Case,1,,male,25.54,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513701,PRJEB14674,Case,1,,male,18.99,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513702,PRJEB14674,Case,1,,male,23.97,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513703,PRJEB14674,Case,1,,female,27.92,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513704,PRJEB14674,Case,1,,male,31.79,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513705,PRJEB14674,Case,1,,female,32.61,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513706,PRJEB14674,Case,1,,female,21.95,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513707,PRJEB14674,Case,1,,male,26.61,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513708,PRJEB14674,Case,1,,male,26.61,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513709,PRJEB14674,Case,1,,male,33.9,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513710,PRJEB14674,Case,1,,male,29.41,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513711,PRJEB14674,Case,1,,male,18.47,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513712,PRJEB14674,Case,1,,male,25.1,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513713,PRJEB14674,Case,1,,male,27.98,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513714,PRJEB14674,Case,1,,male,26.38,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513715,PRJEB14674,Control,0,,male,24.68,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513716,PRJEB14674,Control,0,,male,26.44,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513717,PRJEB14674,Control,0,,female,24.96,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513718,PRJEB14674,Control,0,,female,37.59,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513719,PRJEB14674,Control,0,,male,24.21,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513721,PRJEB14674,Control,0,,female,23.43,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513722,PRJEB14674,Control,0,,female,25.86,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513723,PRJEB14674,Control,0,,male,26.44,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513724,PRJEB14674,Control,0,,male,26.5,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513725,PRJEB14674,Control,0,,male,41.81,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513726,PRJEB14674,Control,0,,female,32.87,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513727,PRJEB14674,Control,0,,male,28.69,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513728,PRJEB14674,Control,0,,male,28.59,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513729,PRJEB14674,Control,0,,female,25.82,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513730,PRJEB14674,Control,0,,female,30.23,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513731,PRJEB14674,Control,0,,male,43.04,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513732,PRJEB14674,Control,0,,female,22.14,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513733,PRJEB14674,Control,0,,female,23.13,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513734,PRJEB14674,Control,0,,male,27.5,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513735,PRJEB14674,Control,0,,female,23.79,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513736,PRJEB14674,Control,0,,male,37.65,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513737,PRJEB14674,Control,0,,female,18.02,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513738,PRJEB14674,Control,0,,female,18.95,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513739,PRJEB14674,Control,0,,male,22.63,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513740,PRJEB14674,Control,0,,female,40.93,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513741,PRJEB14674,Control,0,,female,23.76,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513742,PRJEB14674,Control,0,,female,42.91,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513743,PRJEB14674,Control,0,,female,26.57,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513744,PRJEB14674,Control,0,,female,30.24,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513745,PRJEB14674,Control,0,,male,34.17,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513746,PRJEB14674,Control,0,,male,25.82,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513747,PRJEB14674,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513748,PRJEB14674,Control,0,,male,25.66,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513749,PRJEB14674,Control,0,,male,35.87,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513750,PRJEB14674,Control,0,,female,24.27,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513751,PRJEB14674,Control,0,,female,23.77,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513752,PRJEB14674,Control,0,,male,35.94,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513753,PRJEB14674,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513754,PRJEB14674,Control,0,,male,27.19,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513755,PRJEB14674,Control,0,,male,23.24,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513756,PRJEB14674,Control,0,,male,27.46,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513757,PRJEB14674,Control,0,,female,29.95,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513758,PRJEB14674,Control,0,,female,21.79,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513759,PRJEB14674,Control,0,,female,25.74,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513760,PRJEB14674,Control,0,,female,25.68,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513761,PRJEB14674,Control,0,,female,29.62,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513762,PRJEB14674,Control,0,,male,25.1,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513763,PRJEB14674,Control,0,,female,32,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513764,PRJEB14674,Control,0,,male,29.41,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513765,PRJEB14674,Control,0,,female,20.8,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513766,PRJEB14674,Control,0,,female,29.26,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513767,PRJEB14674,Control,0,,female,39.13,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513768,PRJEB14674,Control,0,,male,26.62,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513769,PRJEB14674,Control,0,,female,39.06,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513770,PRJEB14674,Control,0,,female,29.18,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513771,PRJEB14674,Control,0,,male,23.73,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513772,PRJEB14674,Control,0,,female,20.19,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513773,PRJEB14674,Control,0,,male,22.47,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513775,PRJEB14674,Control,0,,female,21.79,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513776,PRJEB14674,Control,0,,female,32.74,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513777,PRJEB14674,Control,0,,female,22.96,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513778,PRJEB14674,Case,1,,male,40.17,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513779,PRJEB14674,Case,1,,female,22.96,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513780,PRJEB14674,Case,1,,female,22.96,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513781,PRJEB14674,Case,1,,male,31.01,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513782,PRJEB14674,Case,1,,female,18.29,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513783,PRJEB14674,Case,1,,female,24.84,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513784,PRJEB14674,Case,1,,male,26.57,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513785,PRJEB14674,Case,1,,male,24.81,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513786,PRJEB14674,Case,1,,female,26.45,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513787,PRJEB14674,Case,1,,male,26.5,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513788,PRJEB14674,Case,1,,male,25.68,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513789,PRJEB14674,Case,1,,male,25.11,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513790,PRJEB14674,Case,1,,male,22.47,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513793,PRJEB14674,Case,1,,male,21.46,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513794,PRJEB14674,Case,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513795,PRJEB14674,Case,1,,male,26.15,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513796,PRJEB14674,Case,1,,male,23.63,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513797,PRJEB14674,Case,1,,male,30.13,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513798,PRJEB14674,Case,1,,female,18.65,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513799,PRJEB14674,Case,1,,male,21.23,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513800,PRJEB14674,Case,1,,female,31.64,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513801,PRJEB14674,Case,1,,male,23.67,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513802,PRJEB14674,Case,1,,female,19.8,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513803,PRJEB14674,Case,1,,female,14.64,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513804,PRJEB14674,Case,1,,male,27.25,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513805,PRJEB14674,Case,1,,male,30.51,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513806,PRJEB14674,Case,1,,female,18.24,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513807,PRJEB14674,Case,1,,male,25.1,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513808,PRJEB14674,Case,1,,male,24.4,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513810,PRJEB14674,Case,1,,male,27.61,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513811,PRJEB14674,Case,1,,male,30.51,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513812,PRJEB14674,Case,1,,male,37.49,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513813,PRJEB14674,Case,1,,male,30.47,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513815,PRJEB14674,Case,1,,male,30.54,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513816,PRJEB14674,Case,1,,male,20.5,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513817,PRJEB14674,Case,1,,male,24.01,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513819,PRJEB14674,Case,1,,female,20.12,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513820,PRJEB14674,Case,1,,male,30.47,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513821,PRJEB14674,Case,1,,male,24.39,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513822,PRJEB14674,Case,1,,female,19.2,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513823,PRJEB14674,Case,1,,female,37.24,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513825,PRJEB14674,Case,1,,male,31.6,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513826,PRJEB14674,Case,1,,male,19.37,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513827,PRJEB14674,Case,1,,male,25.06,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513828,PRJEB14674,Case,1,,male,22.59,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513829,PRJEB14674,Case,1,,male,22.24,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513830,PRJEB14674,Case,1,,male,26.96,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513831,PRJEB14674,Case,1,,male,28.79,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513832,PRJEB14674,Case,1,,female,30.66,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513833,PRJEB14674,Case,1,,female,22.52,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513834,PRJEB14674,Case,1,,female,19.76,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513835,PRJEB14674,Case,1,,female,26.81,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513836,PRJEB14674,Case,1,,female,28.35,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513837,PRJEB14674,Case,1,,male,29.53,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513838,PRJEB14674,Case,1,,female,34.33,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513839,PRJEB14674,Case,1,,female,33.47,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513840,PRJEB14674,Case,1,,male,30.68,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513841,PRJEB14674,Case,1,,female,19.63,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513842,PRJEB14674,Case,1,,male,40.44,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513843,PRJEB14674,Case,1,,male,22.89,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513844,PRJEB14674,Case,1,,male,27.38,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513845,PRJEB14674,Case,1,,male,26.25,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513846,PRJEB14674,Case,1,,male,30.57,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513847,PRJEB14674,Case,1,,male,30.13,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513849,PRJEB14674,Case,1,,female,30.18,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513850,PRJEB14674,Case,1,,female,17.71,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513851,PRJEB14674,Case,1,,male,23.49,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513853,PRJEB14674,Case,1,,male,30.51,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513854,PRJEB14674,Case,1,,male,30.85,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513856,PRJEB14674,Case,1,,male,28.13,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513857,PRJEB14674,Case,1,,male,31.56,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513858,PRJEB14674,Case,1,,female,20.12,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513859,PRJEB14674,Case,1,,female,22.67,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513860,PRJEB14674,Case,1,,male,30.69,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513861,PRJEB14674,Case,1,,male,22.8,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513862,PRJEB14674,Case,1,,male,23.73,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513863,PRJEB14674,Case,1,,male,26.63,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513864,PRJEB14674,Case,1,,male,24.61,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513865,PRJEB14674,Case,1,,female,22.81,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513866,PRJEB14674,Case,1,,female,20.55,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513867,PRJEB14674,Case,1,,female,23.33,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513868,PRJEB14674,Case,1,,female,26.58,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513869,PRJEB14674,Case,1,,female,18.33,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513870,PRJEB14674,Case,1,,male,25.68,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513871,PRJEB14674,Case,1,,male,27.12,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513872,PRJEB14674,Case,1,,male,25.06,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513873,PRJEB14674,Case,1,,female,27.88,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513874,PRJEB14674,Case,1,,male,25.82,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513875,PRJEB14674,Case,1,,male,24.12,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513876,PRJEB14674,Case,1,,female,31.5,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513877,PRJEB14674,Case,1,,female,21.79,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513878,PRJEB14674,Case,1,,male,24.33,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513879,PRJEB14674,Case,1,,male,31.87,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513880,PRJEB14674,Case,1,,female,22.48,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513881,PRJEB14674,Case,1,,male,18.46,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513882,PRJEB14674,Case,1,,female,26.62,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513883,PRJEB14674,Case,1,,male,25.84,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513884,PRJEB14674,Case,1,,male,32.48,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513885,PRJEB14674,Case,1,,male,31.19,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513886,PRJEB14674,Case,1,,female,20.33,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513887,PRJEB14674,Case,1,,male,26.25,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513889,PRJEB14674,Case,1,,male,30.51,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513890,PRJEB14674,Case,1,,male,25.42,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513891,PRJEB14674,Case,1,,female,17.68,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513892,PRJEB14674,Case,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513894,PRJEB14674,Case,1,,male,20.37,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513896,PRJEB14674,Case,1,,female,34.33,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513898,PRJEB14674,Case,1,,female,22.24,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513899,PRJEB14674,Case,1,,female,30.18,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513900,PRJEB14674,Case,1,,male,22.51,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513901,PRJEB14674,Case,1,,male,26.58,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513902,PRJEB14674,Case,1,,female,18.02,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513903,PRJEB14674,Case,1,,female,22.96,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513904,PRJEB14674,Case,1,,female,21.3,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513905,PRJEB14674,Case,1,,male,31.56,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513906,PRJEB14674,Case,1,,male,25.09,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513907,PRJEB14674,Case,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513908,PRJEB14674,Case,1,,female,22.71,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513909,PRJEB14674,Case,1,,female,20.8,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513910,PRJEB14674,Case,1,,male,27.44,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513911,PRJEB14674,Case,1,,male,22.24,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513912,PRJEB14674,Case,1,,female,38.57,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513913,PRJEB14674,Case,1,,female,25.6,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513914,PRJEB14674,Case,1,,male,27.88,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513915,PRJEB14674,Case,1,,female,23.71,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513916,PRJEB14674,Case,1,,male,24.12,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513917,PRJEB14674,Case,1,,male,33.22,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513918,PRJEB14674,Case,1,,male,28.06,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513919,PRJEB14674,Case,1,,male,26.54,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513920,PRJEB14674,Case,1,,male,29.12,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513921,PRJEB14674,Case,1,,male,33.22,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513922,PRJEB14674,Case,1,,male,31.32,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513923,PRJEB14674,Case,1,,female,22.14,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513924,PRJEB14674,Case,1,,female,24.03,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513925,PRJEB14674,Case,1,,male,29.53,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513926,PRJEB14674,Case,1,,male,25.85,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513927,PRJEB14674,Case,1,,male,18.6,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513928,PRJEB14674,Case,1,,male,26.58,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513929,PRJEB14674,Case,1,,male,23.48,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513930,PRJEB14674,Case,1,,female,19.34,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513931,PRJEB14674,Case,1,,male,27.8,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513932,PRJEB14674,Case,1,,male,31.56,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513933,PRJEB14674,Case,1,,male,24.41,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513934,PRJEB14674,Case,1,,female,40.97,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513935,PRJEB14674,Case,1,,male,35.73,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513936,PRJEB14674,Case,1,,male,21.92,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513939,PRJEB14674,Case,1,,female,45.64,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513940,PRJEB14674,Case,1,,male,23.43,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513941,PRJEB14674,Case,1,,male,30.71,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513942,PRJEB14674,Case,1,,male,19.52,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513943,PRJEB14674,Case,1,,male,26.62,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513944,PRJEB14674,Case,1,,male,24.03,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513945,PRJEB14674,Case,1,,male,24.39,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513946,PRJEB14674,Case,1,,male,24.74,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513947,PRJEB14674,Case,1,,male,25.82,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513948,PRJEB14674,Case,1,,male,25.06,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513949,PRJEB14674,Case,1,,male,27.21,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513950,PRJEB14674,Case,1,,male,43.18,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513951,PRJEB14674,Case,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513952,PRJEB14674,Case,1,,female,30.91,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513953,PRJEB14674,Case,1,,male,25.82,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513954,PRJEB14674,Case,1,,female,25.6,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513955,PRJEB14674,Case,1,,male,25.03,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513956,PRJEB14674,Case,1,,male,35.44,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513957,PRJEB14674,Case,1,,male,21.41,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513958,PRJEB14674,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513959,PRJEB14674,Control,0,,female,28.34,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513960,PRJEB14674,Control,0,,female,24.33,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513961,PRJEB14674,Control,0,,female,24.48,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513963,PRJEB14674,Control,0,,female,36.9,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513964,PRJEB14674,Control,0,,female,33.47,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513965,PRJEB14674,Control,0,,female,24.03,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513966,PRJEB14674,Control,0,,female,22.31,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513967,PRJEB14674,Control,0,,male,23.75,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513968,PRJEB14674,Control,0,,female,27.43,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513969,PRJEB14674,Control,0,,female,24.22,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513970,PRJEB14674,Control,0,,male,30.34,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513971,PRJEB14674,Control,0,,female,21.61,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513972,PRJEB14674,Control,0,,female,24.13,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513973,PRJEB14674,Control,0,,male,24.36,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513974,PRJEB14674,Control,0,,male,33.72,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513975,PRJEB14674,Control,0,,female,28.34,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513976,PRJEB14674,Control,0,,male,22.8,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513977,PRJEB14674,Control,0,,male,23.11,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513978,PRJEB14674,Control,0,,female,34.21,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513979,PRJEB14674,Control,0,,female,34.57,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513980,PRJEB14674,Control,0,,female,32.92,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513981,PRJEB14674,Control,0,,female,21.63,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513982,PRJEB14674,Control,0,,female,33.67,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513983,PRJEB14674,Control,0,,female,25.84,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513984,PRJEB14674,Control,0,,female,17.47,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513985,PRJEB14674,Control,0,,female,34.33,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513986,PRJEB14674,Control,0,,female,23.03,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513987,PRJEB14674,Control,0,,male,24.59,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513988,PRJEB14674,Control,0,,female,22.31,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513989,PRJEB14674,Control,0,,male,25.99,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513990,PRJEB14674,Control,0,,female,32.44,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513991,PRJEB14674,Control,0,,male,28.03,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513992,PRJEB14674,Control,0,,male,30.22,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513993,PRJEB14674,Control,0,,male,24.96,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513994,PRJEB14674,Control,0,,male,27.37,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513995,PRJEB14674,Control,0,,female,23.62,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513996,PRJEB14674,Control,0,,male,29.99,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513997,PRJEB14674,Control,0,,male,29.19,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513998,PRJEB14674,Control,0,,male,25.06,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1513999,PRJEB14674,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1514000,PRJEB14674,Control,0,,male,39.54,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1514001,PRJEB14674,Control,0,,female,33.28,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1514002,PRJEB14674,Control,0,,female,32.77,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1514003,PRJEB14674,Control,0,,male,31.29,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1514005,PRJEB14674,Control,0,,female,33.64,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1514006,PRJEB14674,Control,0,,female,25.06,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1514007,PRJEB14674,Control,0,,male,24.07,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1514008,PRJEB14674,Control,0,,female,44.99,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1514009,PRJEB14674,Control,0,,female,36.49,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1514010,PRJEB14674,Control,0,,female,24.44,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1514011,PRJEB14674,Control,0,,male,30.81,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1514012,PRJEB14674,Control,0,,female,41.96,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1514013,PRJEB14674,Control,0,,female,34.44,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1514014,PRJEB14674,Control,0,,female,27.48,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
ERR1514015,PRJEB14674,Control,0,,female,29.18,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA; REV:GGACTACHVGGGTWTCTAAT,Illumina MiSeq,Parkinsons,Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,PD,
SRS6013266,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013263,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013264,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013262,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013261,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013259,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013260,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013258,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013257,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013256,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013255,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013254,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013253,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013252,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013250,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013251,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013249,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013248,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013246,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013245,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013244,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013243,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013242,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013241,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013240,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013239,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013238,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013237,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013236,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013235,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013234,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013233,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013232,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013230,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013231,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013229,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013228,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013227,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013226,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013225,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013224,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013222,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013221,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013219,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013220,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013218,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013217,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013215,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013214,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013213,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013212,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013211,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013210,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013209,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013208,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013207,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013206,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013205,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013204,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013202,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013203,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013201,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013200,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013199,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013198,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013197,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013196,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013195,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013194,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013193,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013192,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013191,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013190,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013189,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013188,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013187,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013186,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013185,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013184,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013183,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013181,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013182,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013180,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013179,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013178,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013177,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013176,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013175,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013174,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013173,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013172,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013171,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013170,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013169,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013168,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013167,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013166,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013165,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013164,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013163,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013162,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013161,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013160,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013159,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013158,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013157,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013155,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013154,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013153,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013152,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013150,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013151,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013149,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013148,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013147,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013146,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013145,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013144,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013143,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013141,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013142,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013140,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013139,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013138,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013137,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013136,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013135,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013134,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013133,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013132,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013131,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013130,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013129,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013128,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013127,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013126,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013125,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013124,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013123,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013122,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013121,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013120,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013119,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013118,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013117,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013116,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013115,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013113,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013114,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013112,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013111,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013110,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013109,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013108,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013107,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013106,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013105,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013104,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013103,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013102,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013101,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013100,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013099,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013098,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013097,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013096,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013095,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013094,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013093,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013092,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013091,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013090,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013089,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013088,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013087,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013086,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013085,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013084,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013083,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013082,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013081,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013080,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013079,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013078,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013077,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013076,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013075,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013073,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013071,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013070,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013069,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013068,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013067,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013066,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013065,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013064,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013063,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013062,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013061,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013060,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013059,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013058,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013057,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013056,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013054,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013053,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013052,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013051,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013050,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013049,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013048,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013047,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013046,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013045,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013044,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013043,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013042,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013041,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013040,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013039,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013038,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013037,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013036,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013035,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013034,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013033,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013032,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013030,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013028,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013027,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013026,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013025,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013024,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013023,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013022,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013021,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013020,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013018,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013017,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013016,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013015,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013013,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013012,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013011,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013010,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013339,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013338,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013337,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013336,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013335,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013334,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013332,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013333,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013331,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013330,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013329,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013328,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013327,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013326,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013325,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013323,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013324,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013322,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013321,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013320,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013318,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013319,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013317,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013316,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013315,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013314,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013313,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013312,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013311,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013309,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013310,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013308,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013307,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013306,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013304,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013305,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013303,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013302,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013301,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013300,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013299,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013298,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013297,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013296,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013294,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013295,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013293,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013292,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013291,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013290,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013289,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013288,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013287,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013286,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013285,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013284,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013283,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013282,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013280,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013281,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013279,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013278,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013277,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013276,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013275,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013274,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013273,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013272,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013271,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013270,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013269,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013268,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013265,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013595,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013593,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013591,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013592,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013590,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013588,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013587,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013589,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013586,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013585,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013583,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013584,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013582,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013581,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013580,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013579,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013578,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013577,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013576,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013575,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013574,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013573,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013572,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013571,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013570,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013569,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013568,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013567,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013566,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013565,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013564,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013563,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013562,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013561,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013560,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013559,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013557,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013558,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013556,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013555,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013554,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013553,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013552,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013551,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013550,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013549,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013548,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013547,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013545,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013546,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013544,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013542,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013543,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013541,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013540,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013539,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013538,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013537,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013536,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013534,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013535,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013533,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013531,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013532,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013530,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013529,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013528,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013527,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013526,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013525,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013524,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013523,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013522,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013521,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013520,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013519,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013518,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013517,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013516,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013515,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013514,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013513,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013512,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013510,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013511,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013509,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013508,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013507,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013506,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013505,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013504,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013503,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013502,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013501,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013500,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013499,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013498,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013497,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013496,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013495,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013494,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013493,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013492,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013491,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013490,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013488,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013489,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013487,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013486,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013485,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013484,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013483,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013482,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013481,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013480,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013479,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013478,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013477,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013476,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013475,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013474,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013473,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013472,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013471,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013470,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013469,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013468,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013467,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013466,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013465,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013464,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013462,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013461,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013460,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013459,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013458,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013457,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013456,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013455,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013454,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013453,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013452,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013451,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013450,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013449,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013448,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013447,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013446,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013445,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013444,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013442,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013443,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013440,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013441,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013439,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013438,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013437,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013436,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013435,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013434,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013433,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013432,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013431,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013430,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013429,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013428,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013427,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013426,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013425,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013424,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013423,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013422,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013421,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013420,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013419,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013418,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013417,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013416,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013415,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013414,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013413,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013412,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013411,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013410,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013409,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013408,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013407,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013406,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013405,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013404,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013403,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013402,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013401,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013400,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013399,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013398,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013397,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013396,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013395,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013393,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013394,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013392,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013391,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013390,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013389,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013388,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013387,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013386,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013385,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013384,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013383,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013382,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013381,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013380,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013379,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013378,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013377,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013376,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013375,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013373,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013374,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013372,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013371,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013370,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013369,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013368,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013367,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013366,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013365,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013364,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013363,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013362,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013361,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013360,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013359,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013358,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013357,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013356,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013354,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013355,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013352,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013353,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013351,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013350,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013349,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013348,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013347,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013346,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013344,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013345,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013343,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013342,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013340,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013341,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013849,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013847,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013846,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013845,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013844,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013843,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013841,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013842,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013840,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013839,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013838,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013837,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013835,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013836,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013834,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013833,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013832,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013831,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013830,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013829,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013828,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013826,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013827,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013825,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013824,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013823,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013822,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013821,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013820,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013819,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013818,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013817,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013816,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013815,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013814,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013813,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013812,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013811,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013809,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013808,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013807,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013810,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013805,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013803,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013804,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013802,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013801,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013799,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013800,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013798,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013797,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013796,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013795,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013794,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013793,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013792,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013791,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013790,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013788,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013789,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013787,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013786,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013785,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013784,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013783,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013781,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013782,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013780,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013779,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013778,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013777,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013776,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013775,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013774,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013773,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013772,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013771,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013770,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013769,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013768,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013767,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013766,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013765,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013764,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013763,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013762,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013761,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013759,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013760,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013758,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013757,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013756,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013755,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013754,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013752,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013753,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013751,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013750,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013748,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013749,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013747,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013746,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013744,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013745,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013743,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013742,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013741,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013740,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013738,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013739,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013737,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013736,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013735,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013734,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013733,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013732,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013731,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013730,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013728,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013729,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013727,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013726,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013725,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013724,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013723,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013722,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013721,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013720,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013719,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013718,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013717,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013715,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013713,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013714,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013223,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013712,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013711,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013710,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013709,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013708,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013707,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013705,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013706,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013704,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013703,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013702,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013701,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013700,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013699,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013698,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013697,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013696,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013695,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013694,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013693,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013692,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013691,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013690,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013689,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013688,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013687,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013686,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013685,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013684,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013683,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013682,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013681,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013680,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013679,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013678,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013677,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013676,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013675,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013674,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013673,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013672,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013671,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013670,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013669,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013667,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013666,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013668,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013665,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013664,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013663,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013662,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013661,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013660,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013659,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013657,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013658,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013656,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013654,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013655,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013653,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013652,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013651,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013650,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013649,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013648,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013647,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013646,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013645,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013644,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013642,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013643,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013641,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013640,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013639,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013638,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013637,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013636,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013635,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013634,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013633,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013632,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013631,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013630,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013629,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013628,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013627,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013626,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013625,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013624,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013623,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013622,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013621,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013619,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013620,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013618,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013617,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013616,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013615,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013614,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013613,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013612,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013611,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013610,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013609,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013608,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013607,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013606,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013605,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013604,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013603,PRJNA601994,Control,0,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013602,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013601,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013600,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013599,PRJNA601994,Parkinsons,1,,female,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013597,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013598,PRJNA601994,Control,0,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013596,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRS6013594,PRJNA601994,Parkinsons,1,,male,,USA,V4,FWD:GTGCCAGCMGCCGCGGTAA;REV:GTGCCAGCMGCCGCGGTAA,Illumina MiSeq,Parkinsons,Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.,PD,
SRR15012442,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012443,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012444,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012445,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012446,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012447,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012449,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012450,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012451,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012452,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012453,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012454,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012455,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012456,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012457,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012458,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012460,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012461,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012462,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012463,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012464,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012465,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012466,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012467,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012500,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012501,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012503,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012504,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012505,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012506,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012507,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012508,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012509,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012510,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012511,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012512,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012514,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012515,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012516,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012517,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012518,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012519,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012520,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012521,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012522,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012523,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012525,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012526,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012527,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012528,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012529,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012530,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012531,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012532,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012533,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012534,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012537,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012538,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012539,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012540,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012541,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012542,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012543,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012544,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012545,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012546,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012548,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012549,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012550,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012551,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012552,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012553,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012554,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012555,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012556,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012557,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012559,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012560,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012561,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012562,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012563,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012568,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012569,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012570,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012571,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012572,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012574,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012575,PRJNA742875,Parkinson’s disease,1,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012576,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012577,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012578,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012579,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012580,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012581,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012582,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012583,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012585,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012586,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012587,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012588,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012589,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012590,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012591,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012592,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012593,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012594,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012596,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012597,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012598,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012599,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012600,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012601,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012602,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012603,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012604,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012605,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012607,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012608,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012609,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012610,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012611,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012612,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012613,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012614,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012615,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012616,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012618,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012619,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012620,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012621,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012622,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012623,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012624,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012625,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012626,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012627,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012629,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012630,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012631,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012632,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012633,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012634,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012635,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012636,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012637,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012638,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012640,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012641,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012642,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012643,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012644,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012645,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012646,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012647,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012648,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012649,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012652,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012653,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012654,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012655,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012656,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012657,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012658,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012659,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012660,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012661,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012663,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012664,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012665,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012666,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012667,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR15012668,PRJNA742875,healthy,0,,,,Korea,V3-V4,F: CCTACGGGNGGCWGCAG; R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,PD,
SRR10604964,PRJNA594156,Parkinsons,1,23,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604965,PRJNA594156,Parkinsons,1,29,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604966,PRJNA594156,Parkinsons,1,,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604967,PRJNA594156,Parkinsons,1,29,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604968,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604969,PRJNA594156,Control,0,24,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604970,PRJNA594156,Parkinsons,1,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604971,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604972,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604973,PRJNA594156,Control,0,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604974,PRJNA594156,Control,0,21,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604975,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604976,PRJNA594156,Control,0,24,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604977,PRJNA594156,Control,0,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604978,PRJNA594156,Control,0,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604979,PRJNA594156,Control,0,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604980,PRJNA594156,Control,0,25,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604981,PRJNA594156,Control,0,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604982,PRJNA594156,Control,0,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604983,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604984,PRJNA594156,Control,0,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604985,PRJNA594156,Parkinsons,1,25,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604986,PRJNA594156,Control,0,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604987,PRJNA594156,Control,0,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604988,PRJNA594156,Control,0,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604989,PRJNA594156,Control,0,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604990,PRJNA594156,Control,0,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604991,PRJNA594156,Control,0,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604992,PRJNA594156,Control,0,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604993,PRJNA594156,Control,0,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604994,PRJNA594156,Control,0,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604995,PRJNA594156,Control,0,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604996,PRJNA594156,Parkinsons,1,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604997,PRJNA594156,Control,0,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604998,PRJNA594156,Control,0,29,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10604999,PRJNA594156,Control,0,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605000,PRJNA594156,Parkinsons,1,20,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605001,PRJNA594156,Parkinsons,1,22,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605002,PRJNA594156,Control,0,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605003,PRJNA594156,Parkinsons,1,21,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605004,PRJNA594156,Control,0,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605005,PRJNA594156,Parkinsons,1,23,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605006,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605007,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605008,PRJNA594156,Parkinsons,1,24,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605009,PRJNA594156,Control,0,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605010,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605011,PRJNA594156,Parkinsons,1,20,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605012,PRJNA594156,Parkinsons,1,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605013,PRJNA594156,Parkinsons,1,30,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605014,PRJNA594156,Parkinsons,1,25,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605015,PRJNA594156,Control,0,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605016,PRJNA594156,Parkinsons,1,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605017,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605018,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605019,PRJNA594156,Parkinsons,1,30,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605020,PRJNA594156,Parkinsons,1,25,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605021,PRJNA594156,Parkinsons,1,25,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605022,PRJNA594156,Parkinsons,1,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605023,PRJNA594156,Control,0,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605024,PRJNA594156,Control,0,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605025,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605026,PRJNA594156,Parkinsons,1,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605027,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605028,PRJNA594156,Parkinsons,1,23,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605029,PRJNA594156,Control,0,24,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605030,PRJNA594156,Control,0,30,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605031,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605032,PRJNA594156,Control,0,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605033,PRJNA594156,Control,0,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605034,PRJNA594156,Control,0,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605035,PRJNA594156,Control,0,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605036,PRJNA594156,Control,0,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605037,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605038,PRJNA594156,Control,0,22,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605039,PRJNA594156,Control,0,23,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605040,PRJNA594156,Control,0,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605041,PRJNA594156,Control,0,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605042,PRJNA594156,Control,0,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605043,PRJNA594156,Control,0,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605044,PRJNA594156,Control,0,30,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605045,PRJNA594156,Control,0,21,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605046,PRJNA594156,Control,0,30,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605047,PRJNA594156,Control,0,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605048,PRJNA594156,Parkinsons,1,,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605049,PRJNA594156,Control,0,30,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605050,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605051,PRJNA594156,Parkinsons,1,17,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605052,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605053,PRJNA594156,Parkinsons,1,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605054,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605055,PRJNA594156,Parkinsons,1,25,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605056,PRJNA594156,Parkinsons,1,30,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605057,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605058,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605059,PRJNA594156,Control,0,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605060,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605061,PRJNA594156,Parkinsons,1,21,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605062,PRJNA594156,Parkinsons,1,24,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605063,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605064,PRJNA594156,Parkinsons,1,17,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605065,PRJNA594156,Parkinsons,1,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605066,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605067,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605068,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605069,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605070,PRJNA594156,Control,0,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605071,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605072,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605073,PRJNA594156,Parkinsons,1,23,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605074,PRJNA594156,Control,0,19,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605075,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605076,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605077,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605078,PRJNA594156,Parkinsons,1,23,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605079,PRJNA594156,Control,0,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605080,PRJNA594156,Parkinsons,1,22,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605081,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605082,PRJNA594156,Parkinsons,1,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605083,PRJNA594156,Parkinsons,1,24,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605084,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605085,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605086,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605087,PRJNA594156,Parkinsons,1,30,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605088,PRJNA594156,Parkinsons,1,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605089,PRJNA594156,Parkinsons,1,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605090,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605091,PRJNA594156,Parkinsons,1,22,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605092,PRJNA594156,Parkinsons,1,30,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605093,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605094,PRJNA594156,Parkinsons,1,29,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605095,PRJNA594156,Parkinsons,1,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605096,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605097,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605098,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605099,PRJNA594156,Control,0,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605100,PRJNA594156,Parkinsons,1,29,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605101,PRJNA594156,Parkinsons,1,20,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605102,PRJNA594156,Parkinsons,1,22,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605103,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605104,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605105,PRJNA594156,Parkinsons,1,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605106,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605107,PRJNA594156,Parkinsons,1,24,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605108,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605109,PRJNA594156,Parkinsons,1,29,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605110,PRJNA594156,Parkinsons,1,23,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605111,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605112,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605113,PRJNA594156,Control,0,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605114,PRJNA594156,Parkinsons,1,23,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605115,PRJNA594156,Control,0,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605116,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605117,PRJNA594156,Parkinsons,1,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605118,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605119,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605120,PRJNA594156,Parkinsons,1,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605121,PRJNA594156,Parkinsons,1,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605122,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605123,PRJNA594156,Parkinsons,1,23,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605124,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605125,PRJNA594156,Control,0,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605126,PRJNA594156,Parkinsons,1,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605127,PRJNA594156,Parkinsons,1,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605128,PRJNA594156,Parkinsons,1,23,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605129,PRJNA594156,Parkinsons,1,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605130,PRJNA594156,Parkinsons,1,22,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605131,PRJNA594156,Parkinsons,1,25,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605132,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605133,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605134,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605135,PRJNA594156,Parkinsons,1,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605136,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605137,PRJNA594156,Parkinsons,1,29,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605138,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605139,PRJNA594156,Control,0,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605140,PRJNA594156,Control,0,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605141,PRJNA594156,Parkinsons,1,30,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605142,PRJNA594156,Parkinsons,1,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605143,PRJNA594156,Control,0,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605144,PRJNA594156,Parkinsons,1,24,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605145,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605146,PRJNA594156,Parkinsons,1,30,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605147,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605148,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605149,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605150,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605151,PRJNA594156,Control,0,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605152,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605153,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605154,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605155,PRJNA594156,Control,0,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605156,PRJNA594156,Parkinsons,1,30,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605157,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605158,PRJNA594156,Control,0,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605159,PRJNA594156,Control,0,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605160,PRJNA594156,Control,0,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605161,PRJNA594156,Parkinsons,1,24,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605162,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605163,PRJNA594156,Control,0,29,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605164,PRJNA594156,Control,0,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605165,PRJNA594156,Parkinsons,1,21,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605166,PRJNA594156,Control,0,30,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605167,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605168,PRJNA594156,Parkinsons,1,29,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605169,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605170,PRJNA594156,Control,0,30,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605171,PRJNA594156,Control,0,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605172,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605173,PRJNA594156,Parkinsons,1,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605174,PRJNA594156,Control,0,19,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605175,PRJNA594156,Parkinsons,1,24,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605176,PRJNA594156,Parkinsons,1,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605177,PRJNA594156,Control,0,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605178,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605179,PRJNA594156,Control,0,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605180,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605181,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605182,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605183,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605184,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605185,PRJNA594156,Control,0,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605186,PRJNA594156,Parkinsons,1,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605187,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605188,PRJNA594156,Control,0,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605189,PRJNA594156,Control,0,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605190,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605191,PRJNA594156,Parkinsons,1,31,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605192,PRJNA594156,Control,0,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605193,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605194,PRJNA594156,Parkinsons,1,29,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605195,PRJNA594156,Parkinsons,1,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605196,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605197,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605198,PRJNA594156,Control,0,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605199,PRJNA594156,Parkinsons,1,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605200,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605201,PRJNA594156,Parkinsons,1,29,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605202,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605203,PRJNA594156,Parkinsons,1,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605204,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605205,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605206,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605207,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605208,PRJNA594156,Control,0,24,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605209,PRJNA594156,Control,0,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605210,PRJNA594156,Control,0,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605211,PRJNA594156,Control,0,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605212,PRJNA594156,Control,0,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605213,PRJNA594156,Control,0,24,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605214,PRJNA594156,Control,0,24,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605215,PRJNA594156,Control,0,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605216,PRJNA594156,Control,0,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605217,PRJNA594156,Control,0,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605218,PRJNA594156,Control,0,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605219,PRJNA594156,Control,0,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605220,PRJNA594156,Control,0,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605221,PRJNA594156,Control,0,25,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605222,PRJNA594156,Control,0,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605223,PRJNA594156,Control,0,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605224,PRJNA594156,Control,0,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605225,PRJNA594156,Control,0,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605226,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605227,PRJNA594156,Control,0,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605228,PRJNA594156,Control,0,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605229,PRJNA594156,Control,0,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605230,PRJNA594156,Control,0,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605231,PRJNA594156,Control,0,25,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605232,PRJNA594156,Parkinsons,1,25,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605233,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605234,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605235,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605236,PRJNA594156,Parkinsons,1,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605237,PRJNA594156,Parkinsons,1,15,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605238,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605239,PRJNA594156,Parkinsons,1,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605240,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605241,PRJNA594156,Parkinsons,1,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605242,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605243,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605244,PRJNA594156,Control,0,23,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605245,PRJNA594156,Parkinsons,1,29,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605246,PRJNA594156,Parkinsons,1,25,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605247,PRJNA594156,Parkinsons,1,26,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605248,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605249,PRJNA594156,Control,0,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605250,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605251,PRJNA594156,Parkinsons,1,21,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605252,PRJNA594156,Parkinsons,1,26,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605253,PRJNA594156,Parkinsons,1,27,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605254,PRJNA594156,Parkinsons,1,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605255,PRJNA594156,Parkinsons,1,28,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605256,PRJNA594156,Parkinsons,1,24,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605257,PRJNA594156,Parkinsons,1,28,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605258,PRJNA594156,Parkinsons,1,30,female,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605259,PRJNA594156,Control,0,27,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605260,PRJNA594156,Parkinsons,1,29,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605261,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605262,PRJNA594156,Parkinsons,1,25,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
SRR10605263,PRJNA594156,Parkinsons,1,29,male,,Canada,V4,F: GTGCCAGCMGCCGCGGTAA; R: GGACTACHVHHHTWTCTAAT,ILLUMINA,Parkinson's patients,Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease,PD,
ERR3046385,PRJEB30615,Parkinson's disease,1,50,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046388,PRJEB30615,Parkinson's disease,1,0,,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046393,PRJEB30615,Parkinson's disease,1,68,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046395,PRJEB30615,Parkinson's disease,1,67,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046398,PRJEB30615,Parkinson's disease,1,69,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046399,PRJEB30615,Parkinson's disease,1,75,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046401,PRJEB30615,Parkinson's disease,1,72,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046403,PRJEB30615,Parkinson's disease,1,60,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046422,PRJEB30615,Parkinson's disease,1,77,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046427,PRJEB30615,healthy control,0,61,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046429,PRJEB30615,healthy control,0,66,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046430,PRJEB30615,healthy control,0,65,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046432,PRJEB30615,healthy control,0,67,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046433,PRJEB30615,healthy control,0,63,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046434,PRJEB30615,healthy control,0,72,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046439,PRJEB30615,healthy control,0,56,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046440,PRJEB30615,healthy control,0,56,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046444,PRJEB30615,healthy control,0,74,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046449,PRJEB30615,Parkinson's disease,1,50,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046450,PRJEB30615,Parkinson's disease,1,78,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046452,PRJEB30615,Parkinson's disease,1,0,,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046455,PRJEB30615,Parkinson's disease,1,74,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046458,PRJEB30615,Parkinson's disease,1,74,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046459,PRJEB30615,Parkinson's disease,1,67,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046462,PRJEB30615,Parkinson's disease,1,69,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046466,PRJEB30615,Parkinson's disease,1,53,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046467,PRJEB30615,Parkinson's disease,1,60,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046470,PRJEB30615,Parkinson's disease,1,67,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046473,PRJEB30615,Parkinson's disease,1,75,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046475,PRJEB30615,Parkinson's disease,1,53,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046478,PRJEB30615,Parkinson's disease,1,61,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046481,PRJEB30615,Parkinson's disease,1,62,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046491,PRJEB30615,healthy control,0,61,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046493,PRJEB30615,healthy control,0,66,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046494,PRJEB30615,healthy control,0,65,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046495,PRJEB30615,healthy control,0,64,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046497,PRJEB30615,healthy control,0,63,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046498,PRJEB30615,healthy control,0,72,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046499,PRJEB30615,healthy control,0,70,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046500,PRJEB30615,healthy control,0,63,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046501,PRJEB30615,healthy control,0,59,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046502,PRJEB30615,healthy control,0,57,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046505,PRJEB30615,healthy control,0,55,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046510,PRJEB30615,healthy control,0,70,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046513,PRJEB30615,Parkinson's disease,1,50,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046517,PRJEB30615,Parkinson's disease,1,0,,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046523,PRJEB30615,Parkinson's disease,1,67,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046526,PRJEB30615,Parkinson's disease,1,69,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046528,PRJEB30615,Parkinson's disease,1,70,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046531,PRJEB30615,Parkinson's disease,1,60,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046537,PRJEB30615,Parkinson's disease,1,75,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046548,PRJEB30615,Parkinson's disease,1,77,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046551,PRJEB30615,Parkinson's disease,1,0,,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046556,PRJEB30615,healthy control,0,63,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046561,PRJEB30615,healthy control,0,63,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046562,PRJEB30615,healthy control,0,72,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046568,PRJEB30615,healthy control,0,56,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046573,PRJEB30615,healthy control,0,66,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046583,PRJEB30615,Parkinson's disease,1,74,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046587,PRJEB30615,Parkinson's disease,1,67,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046588,PRJEB30615,Parkinson's disease,1,78,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046589,PRJEB30615,Parkinson's disease,1,66,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046590,PRJEB30615,Parkinson's disease,1,69,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046594,PRJEB30615,Parkinson's disease,1,53,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046596,PRJEB30615,Parkinson's disease,1,69,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046601,PRJEB30615,Parkinson's disease,1,75,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046605,PRJEB30615,Parkinson's disease,1,62,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046614,PRJEB30615,Parkinson's disease,1,77,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046617,PRJEB30615,healthy control,0,61,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046620,PRJEB30615,healthy control,0,63,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046621,PRJEB30615,healthy control,0,66,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046623,PRJEB30615,healthy control,0,64,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046625,PRJEB30615,healthy control,0,63,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046632,PRJEB30615,healthy control,0,56,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046634,PRJEB30615,healthy control,0,76,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046636,PRJEB30615,healthy control,0,74,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046637,PRJEB30615,healthy control,0,66,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046638,PRJEB30615,healthy control,0,70,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046386,PRJEB30615,Parkinson's disease,1,78,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046387,PRJEB30615,Parkinson's disease,1,65,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046389,PRJEB30615,Parkinson's disease,1,0,,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046390,PRJEB30615,Parkinson's disease,1,47,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046391,PRJEB30615,Parkinson's disease,1,74,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046392,PRJEB30615,Parkinson's disease,1,60,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046394,PRJEB30615,Parkinson's disease,1,74,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046396,PRJEB30615,Parkinson's disease,1,78,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046397,PRJEB30615,Parkinson's disease,1,66,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046400,PRJEB30615,Parkinson's disease,1,70,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046402,PRJEB30615,Parkinson's disease,1,53,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046404,PRJEB30615,Parkinson's disease,1,69,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046405,PRJEB30615,Parkinson's disease,1,78,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046406,PRJEB30615,Parkinson's disease,1,67,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046407,PRJEB30615,Parkinson's disease,1,81,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046408,PRJEB30615,Parkinson's disease,1,74,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046409,PRJEB30615,Parkinson's disease,1,75,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046410,PRJEB30615,Parkinson's disease,1,69,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046411,PRJEB30615,Parkinson's disease,1,53,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046412,PRJEB30615,Parkinson's disease,1,0,,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046413,PRJEB30615,Parkinson's disease,1,62,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046414,PRJEB30615,Parkinson's disease,1,61,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046415,PRJEB30615,Parkinson's disease,1,74,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046416,PRJEB30615,Parkinson's disease,1,59,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046417,PRJEB30615,Parkinson's disease,1,62,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046418,PRJEB30615,Parkinson's disease,1,67,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046419,PRJEB30615,Parkinson's disease,1,77,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046420,PRJEB30615,Parkinson's disease,1,77,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046421,PRJEB30615,Parkinson's disease,1,77,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046423,PRJEB30615,Parkinson's disease,1,0,,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046424,PRJEB30615,healthy control,0,58,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046425,PRJEB30615,healthy control,0,61,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046426,PRJEB30615,healthy control,0,55,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046428,PRJEB30615,healthy control,0,63,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046431,PRJEB30615,healthy control,0,64,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046435,PRJEB30615,healthy control,0,70,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046436,PRJEB30615,healthy control,0,63,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046437,PRJEB30615,healthy control,0,59,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046438,PRJEB30615,healthy control,0,57,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046441,PRJEB30615,healthy control,0,55,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046442,PRJEB30615,healthy control,0,76,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046443,PRJEB30615,healthy control,0,71,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046445,PRJEB30615,healthy control,0,66,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046446,PRJEB30615,healthy control,0,70,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046447,PRJEB30615,healthy control,0,64,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046448,PRJEB30615,healthy control,0,64,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046451,PRJEB30615,Parkinson's disease,1,65,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046453,PRJEB30615,Parkinson's disease,1,0,,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046454,PRJEB30615,Parkinson's disease,1,47,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046456,PRJEB30615,Parkinson's disease,1,60,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046457,PRJEB30615,Parkinson's disease,1,68,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046460,PRJEB30615,Parkinson's disease,1,78,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046461,PRJEB30615,Parkinson's disease,1,66,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046463,PRJEB30615,Parkinson's disease,1,75,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046464,PRJEB30615,Parkinson's disease,1,70,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046465,PRJEB30615,Parkinson's disease,1,72,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046468,PRJEB30615,Parkinson's disease,1,69,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046469,PRJEB30615,Parkinson's disease,1,78,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046471,PRJEB30615,Parkinson's disease,1,81,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046472,PRJEB30615,Parkinson's disease,1,74,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046474,PRJEB30615,Parkinson's disease,1,69,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046476,PRJEB30615,Parkinson's disease,1,0,,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046477,PRJEB30615,Parkinson's disease,1,62,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046479,PRJEB30615,Parkinson's disease,1,74,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046480,PRJEB30615,Parkinson's disease,1,59,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046482,PRJEB30615,Parkinson's disease,1,67,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046483,PRJEB30615,Parkinson's disease,1,77,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046484,PRJEB30615,Parkinson's disease,1,77,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046485,PRJEB30615,Parkinson's disease,1,77,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046486,PRJEB30615,Parkinson's disease,1,77,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046487,PRJEB30615,Parkinson's disease,1,0,,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046488,PRJEB30615,healthy control,0,58,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046489,PRJEB30615,healthy control,0,61,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046490,PRJEB30615,healthy control,0,55,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046492,PRJEB30615,healthy control,0,63,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046496,PRJEB30615,healthy control,0,67,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046503,PRJEB30615,healthy control,0,56,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046504,PRJEB30615,healthy control,0,56,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046506,PRJEB30615,healthy control,0,76,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046507,PRJEB30615,healthy control,0,71,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046508,PRJEB30615,healthy control,0,74,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046509,PRJEB30615,healthy control,0,66,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046511,PRJEB30615,healthy control,0,64,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046512,PRJEB30615,healthy control,0,64,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046514,PRJEB30615,Parkinson's disease,1,78,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046515,PRJEB30615,Parkinson's disease,1,65,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046516,PRJEB30615,Parkinson's disease,1,0,,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046518,PRJEB30615,Parkinson's disease,1,47,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046519,PRJEB30615,Parkinson's disease,1,74,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046520,PRJEB30615,Parkinson's disease,1,60,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046521,PRJEB30615,Parkinson's disease,1,68,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046522,PRJEB30615,Parkinson's disease,1,74,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046524,PRJEB30615,Parkinson's disease,1,78,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046525,PRJEB30615,Parkinson's disease,1,66,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046527,PRJEB30615,Parkinson's disease,1,75,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046529,PRJEB30615,Parkinson's disease,1,72,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046530,PRJEB30615,Parkinson's disease,1,53,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046532,PRJEB30615,Parkinson's disease,1,69,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046533,PRJEB30615,Parkinson's disease,1,78,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046534,PRJEB30615,Parkinson's disease,1,67,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046535,PRJEB30615,Parkinson's disease,1,81,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046536,PRJEB30615,Parkinson's disease,1,74,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046538,PRJEB30615,Parkinson's disease,1,69,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046539,PRJEB30615,Parkinson's disease,1,53,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046540,PRJEB30615,Parkinson's disease,1,0,,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046541,PRJEB30615,Parkinson's disease,1,62,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046542,PRJEB30615,Parkinson's disease,1,61,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046543,PRJEB30615,Parkinson's disease,1,74,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046544,PRJEB30615,Parkinson's disease,1,59,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046545,PRJEB30615,Parkinson's disease,1,62,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046546,PRJEB30615,Parkinson's disease,1,67,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046547,PRJEB30615,Parkinson's disease,1,77,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046549,PRJEB30615,Parkinson's disease,1,77,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046550,PRJEB30615,Parkinson's disease,1,77,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046552,PRJEB30615,healthy control,0,58,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046553,PRJEB30615,healthy control,0,61,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046554,PRJEB30615,healthy control,0,55,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046555,PRJEB30615,healthy control,0,61,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046557,PRJEB30615,healthy control,0,66,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046558,PRJEB30615,healthy control,0,65,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046559,PRJEB30615,healthy control,0,64,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046560,PRJEB30615,healthy control,0,67,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046563,PRJEB30615,healthy control,0,70,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046564,PRJEB30615,healthy control,0,63,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046565,PRJEB30615,healthy control,0,59,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046566,PRJEB30615,healthy control,0,57,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046567,PRJEB30615,healthy control,0,56,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046569,PRJEB30615,healthy control,0,55,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046570,PRJEB30615,healthy control,0,76,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046571,PRJEB30615,healthy control,0,71,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046572,PRJEB30615,healthy control,0,74,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046574,PRJEB30615,healthy control,0,70,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046575,PRJEB30615,healthy control,0,64,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046576,PRJEB30615,healthy control,0,64,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046577,PRJEB30615,Parkinson's disease,1,50,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046578,PRJEB30615,Parkinson's disease,1,78,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046579,PRJEB30615,Parkinson's disease,1,65,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046580,PRJEB30615,Parkinson's disease,1,0,,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046581,PRJEB30615,Parkinson's disease,1,0,,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046582,PRJEB30615,Parkinson's disease,1,47,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046584,PRJEB30615,Parkinson's disease,1,60,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046585,PRJEB30615,Parkinson's disease,1,68,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046586,PRJEB30615,Parkinson's disease,1,74,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046591,PRJEB30615,Parkinson's disease,1,75,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046592,PRJEB30615,Parkinson's disease,1,70,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046593,PRJEB30615,Parkinson's disease,1,72,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046595,PRJEB30615,Parkinson's disease,1,60,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046597,PRJEB30615,Parkinson's disease,1,78,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046598,PRJEB30615,Parkinson's disease,1,67,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046599,PRJEB30615,Parkinson's disease,1,81,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046600,PRJEB30615,Parkinson's disease,1,74,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046602,PRJEB30615,Parkinson's disease,1,69,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046603,PRJEB30615,Parkinson's disease,1,53,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046604,PRJEB30615,Parkinson's disease,1,0,,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046606,PRJEB30615,Parkinson's disease,1,61,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046607,PRJEB30615,Parkinson's disease,1,74,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046608,PRJEB30615,Parkinson's disease,1,59,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046609,PRJEB30615,Parkinson's disease,1,62,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046610,PRJEB30615,Parkinson's disease,1,67,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046611,PRJEB30615,Parkinson's disease,1,77,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046612,PRJEB30615,Parkinson's disease,1,77,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046613,PRJEB30615,Parkinson's disease,1,77,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046615,PRJEB30615,Parkinson's disease,1,0,,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046616,PRJEB30615,healthy control,0,58,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046618,PRJEB30615,healthy control,0,55,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046619,PRJEB30615,healthy control,0,61,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046622,PRJEB30615,healthy control,0,65,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046624,PRJEB30615,healthy control,0,67,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046626,PRJEB30615,healthy control,0,72,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046627,PRJEB30615,healthy control,0,70,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046628,PRJEB30615,healthy control,0,63,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046629,PRJEB30615,healthy control,0,59,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046630,PRJEB30615,healthy control,0,57,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046631,PRJEB30615,healthy control,0,56,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046633,PRJEB30615,healthy control,0,55,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046635,PRJEB30615,healthy control,0,71,male,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046639,PRJEB30615,healthy control,0,64,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR3046640,PRJEB30615,healthy control,0,64,female,,Germany,V4-V5,F: AYTGGGYDTAAAGNG; R: CCGTCAATTCMTTTRAGTTT,ILLUMINA,Parkinson's patients,Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota,PD,
ERR2730148,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730149,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730150,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730151,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730152,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730153,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730154,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730155,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730156,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730157,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730158,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730159,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730160,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730161,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730162,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730163,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730164,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730165,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730166,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730167,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730168,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730169,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730170,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730171,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730172,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730173,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730174,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730175,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730176,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730177,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730178,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730179,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730180,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730181,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730182,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730183,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730184,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730185,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730186,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730187,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730188,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730189,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730190,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730191,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730192,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730193,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730194,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730195,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730196,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730197,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730198,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730199,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730200,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730201,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730202,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730203,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730204,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730205,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730206,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730207,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730208,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730209,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730210,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730211,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730212,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730213,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730214,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730215,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730216,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730217,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730218,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730219,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730220,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730221,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730222,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730223,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730224,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730225,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730226,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730227,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730228,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730229,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730230,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730231,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730232,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730233,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730234,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730235,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730236,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730237,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730238,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730239,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730240,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730241,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730242,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730243,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730244,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730245,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730246,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730247,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730248,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730249,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730250,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730251,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730252,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730253,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730254,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730255,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730256,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730257,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730258,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730259,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730260,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730261,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730262,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730263,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730264,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730265,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730266,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730267,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730268,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730269,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730270,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730271,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730272,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730273,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730274,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730275,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730276,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730277,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730278,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730279,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730280,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730281,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730282,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730283,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730284,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730285,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730286,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730287,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730288,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730289,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730290,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730291,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730292,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730293,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730294,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730295,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730296,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730297,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730298,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730299,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730300,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730301,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730302,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730303,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730304,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730305,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730306,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730307,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730308,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730309,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730310,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730311,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730312,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730313,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730314,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730315,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730316,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730317,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730318,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730319,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730320,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730321,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730322,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730323,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730324,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730325,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730326,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730327,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730328,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730329,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730330,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730331,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730332,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730333,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730334,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730335,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730336,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730337,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730338,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730339,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730340,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730341,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730342,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730343,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730344,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730345,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730346,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730347,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730348,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730349,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730350,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730351,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730352,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730353,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730354,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730355,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730356,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730357,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730358,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730359,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730360,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730361,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730362,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730363,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730364,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730365,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730366,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730367,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730368,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730369,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730370,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730371,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730372,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730373,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730374,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730375,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730376,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730377,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730378,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730379,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730380,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730381,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730382,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730383,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730384,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730385,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730386,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730387,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730388,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730389,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730390,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730391,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730392,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730393,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730394,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730395,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730396,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730397,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730398,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730399,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730400,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730401,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730402,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR2730403,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR3040009,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR3040010,PRJEB27564,control,0,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR3040011,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR3040012,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR3040013,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR3040014,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR3040015,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR3040016,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR3040017,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
ERR3040018,PRJEB27564,Parkinson’s disease,1,,,,Finland,V3-V4,F: CCTACGGGNGGCWGCAG;  R: GACTACHVGGGTATCTAATCC,ILLUMINA,Parkinson's patients,Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,PD,
